Prospective-Retrospective Analysis of PTEN Immunohistochemistry Assay for Prediction of Outcomes in Recurrent and Metastatic Prostate Cancer
Technical Report,01 Sep 2017,31 Aug 2018
Johns Hopkins University Baltimore United States
Pagination or Media Count:
As part of the CDMRP-funded Precision Medicine Biomarker Validating Center, we have developed a robust, highly analytically validated and cost-effective immunohistochemistry IHC-based assay to interrogate PTEN loss in prostate cancer. Our PTEN assay is prognostic in multiple cohorts of surgically-treated prostate cancer patients now, we propose to leverage this body of previous validation studies to test the hypothesis that PTEN loss in primary prostate cancer predicts for a less robust response to hormonal therapies, in the context of two recent, practice-changing Phase III clinical trials for which we have CTEP approval to access specimens. Here, we report on progress to date. We have obtained and immunostained slides from ECOG3805 CHAARTED for PTEN. In analyses, we have examined the association of PTEN loss with outcomes in the androgen deprivation therapyADT arm n119 and the ADTDocetaxel arm n108. We find that PTEN loss is not a significant predictor overall survival in the trial as a whole and is actually protective in the setting of high volume metastatic disease.
- Medicine and Medical Research